That humans in endemic areas become immune to malaria offers encouragement to the
idea of developing protective vaccines. However natural immunity is relatively inefficient …

Early data emerging from the first phase 3 trial of a malaria vaccine are raising hopes that a
licensed vaccine will soon be available for use in endemic countries, but given the relatively …

The development of effective malaria vaccines may be hindered by extensive genetic
diversity in the surface proteins being employed as vaccine antigens. Understanding of the …

The C-terminal 19-kDa fragment of Plasmodium falciparum merozoite surface protein-1
(MSP-1 19) is a target of protective Abs against blood-stage infection and a leading …

Over the last 30 years, evidence has been gathered suggesting that merozoite surface
protein 1 (MSP1) is a target of protective immunity against malaria. In a variety of …

Background Plasmodium falciparum in vitro growth inhibition assays are widely used to
evaluate and quantify the functional activity of acquired and vaccine-induced antibodies and …

Antibodies to the C terminus of the Plasmodium falciparum merozoite surface protein,
PfMSP-119, may inhibit merozoite invasion or block the effects of inhibitory antibodies. Here …

Background Antibodies that inhibit the growth of blood-stage Plasmodium falciparum may
play an important role in acquired and vaccine-induced immunity in humans. However, the …

Background Malaria vaccines based on the 19-kDa region of merozoite surface protein 1
(MSP-119) derived from the 3D7 strain of Plasmodium falciparum are being tested in clinical …

Malaria reflects not only a state of immune activation, but also a state of general immune
defect or immunosuppression, of complex etiology that can last longer than the actual …